Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Smit, Mikaela ^a   Smit, Colette ^b   Geerlings, Suzanne ^c   Gras, Luuk ^b   Brinkman, Kees ^d   Hallett, Timothy B ^a   de Wolf, Frank ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b STICHTING HIV MONITORING   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; COMBINATION ANTIRETROVIRAL THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; NETHERLANDS; NEUROTOXICITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; SKIN TOXICITY; TREND STUDY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84884787254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076071     Document Type: Article

References (42)

1. FDA (2012) Antiretroviral drugs used in the treatment of HIV infection- Drugs Used in the Treatment of HIV Infection. Available: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaidsactivities/ucm118915.htm. Accessed 12 June 2010.
2. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, et al. (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2293-2303 doi:10.1056/NEJMoa030264.
3. Dubé M, Zackin R, Tebas R, Roubenoff R, Mulligan K, et al. (2002) Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384. Antiretroviral Therapy 7: L27.
4. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201 doi:10.1001/jama.292.2.191.
5. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260 doi:10.1056/NEJMoa051871.
6. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. (2007) Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 8: 679-688 doi:10.1517/14656566.8.5.679.
7. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, et al. (2001) Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27: 237-244.
8. Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, et al. (1998) The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 12: 619-624.
9. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, et al. (1999) Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 13: F9-16.
10. Madruga JRV, Cassetti I, Suleiman JMAH, Etzel A, Zhong L, et al. (2007) The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials 8: 381-390 doi:10.1310/hct0806-381.
11. Pozniak A, Gallant JE, DeJesus E, Arribas JR, Gazzard B, et al. (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 43: 535-540 doi:10.1097/01.qai.0000245886.51262.67.
12. Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, et al. (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47: 74-78 doi:10.1097/QAI.0b013e31815acab8.
13. Van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, et al. (2003) Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 17: 2227-2236 doi:10.1097/01.aids.0000088199.77946.17.
14. Smit M, Smit C, Cremin I, Garnett GP, Hallett T, et al. (2012) Could better tolerated HIV drug regimens improve patient outcome? AIDS 26: 1953-1959 doi:10.1097/QAD.0b013e32835722bd.
15. European AIDS Clinical Society (2011) Guidelines. Available: http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41.
16. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson A, et al. (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300: 51-59.
17. Nederlandse Verening van HIV-Behandelaren (2012) Richtlijn HIV. Available: http://www.nvhb.nl/richtlijnhiv/index.php/Hoofdpagina. Accessed 10 January 2012.
18. Wandeler G, Keiser O, Hirschel B, Günthard HF, Bernasconi E, et al. (2011) A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. PLoS ONE 6: e27903 doi:10.1371/journal.pone.0027903.
19. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 22-29.
20. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, et al. (2010) Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65 doi:10.1001/archinternmed.2009.432.
21. D' Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000) Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 14: 499-507.
22. Yuan Y, L'italien G, Mukherjee J, Iloeje UH, (2006) Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 7: 156-162 doi:10.1111/j.1468-1293.2006.00355.x.
23. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, et al. (2005) Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Available: http://eprints.ucl.ac.uk/1229/. Accessed 22 August 2011.
24. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, et al. (2008) Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 22: 1951-1960 doi:10.1097/QAD.0b013e32830efd79.
25. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
26. Doll R, Hill A, (1954) The mortality of doctors in relation to their smoking habits; a preliminary report. British Medical Journal 1: 1451-1455.
27. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, et al. (2011) Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 66: 2107-2111 doi:10.1093/jac/dkr248.
28. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, et al. (1999) Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. The Lancet 353: 863-868 doi:10.1016/S0140-6736(99)01122-8.
29. Ofotokun I, Chuck SK, Hitti JE, (2007) Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 4: 106-119.
30. Floridia M, Giuliano M, Palmisano L, Vella S, (2008) Gender differences in the treatment of HIV infection. Pharmacol Res 58: 173-182 doi:10.1016/j.phrs.2008.07.007.
31. Portsmouth SD, Scott CJ, (2007) The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag 3: 579-583.
32. Carr A, Miller J, Law M, Cooper DA, (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: F25-32.
33. Falcó V, Crespo M, Ribera E, (2003) Lactic acidosis related to nucleoside therapy in HIV-infected patients. Expert Opin Pharmacother 4: 1321-1329 doi:10.1517/14656566.4.8.1321.
34. Martin A, Smith DE, Carr A, Ringland C, Amin J, et al. (2004) Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18: 1029-1036.
35. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, et al. (2000) Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe: Results From the EuroSIDA Study. Arch Intern Med 160: 1123-1132 doi:10.1001/archinte.160.8.1123.
36. Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. (2005) Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19: 577-583.
37. Van Griensven J, Thai S, (2011) Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. Trans R Soc Trop Med Hyg 105: 694-703 doi:10.1016/j.trstmh.2011.08.007.
38. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, et al. (2012) Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis 12: 296 doi:10.1186/1471-2334-12-296.
39. Robison LS, Westfall AO, Mugavero MJ, Kempf MC, Cole SR, et al. (2008) Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 24: 1347-1355 doi:10.1089/aid.2008.0083.
40. Gilead Sciences and Bristol-Myers Squibb (2010) Atripla. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021937s019lbl.pdf. Accessed 15 December 2010.
41. Gilead Sciences (2009) Truvada. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021752s019lbl.pdf. Accessed 20 May 2011.
42. Hernán MA, Brumback B, Robins JM, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570.